Starting January 1, 2027, Medicare will pay most 340B hospitals ASP minus 28% for separately payable Part B drugs bought at 340B prices. Today it pays ASP plus 6%. CMS finalized the change in its CY 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule, issued November 4, 2026. For many hospitals, the question now is drug by drug: buy on 340B, or buy outside 340B for Medicare patients?
What changed
- 340B-purchased drugs: paid at ASP minus 28%. CMS had proposed ASP minus 33.4%.
- Drugs bought outside 340B: still paid at the regular OPPS rate, generally ASP plus 6%.
- Other outpatient payments: the law requires the cut to be budget neutral, so CMS raises payment for non-drug outpatient services for all OPPS hospitals, by an estimated 7.5%.
Who is exempt
- Rural sole community hospitals, children's hospitals and PPS-exempt cancer hospitals.
- Critical access hospitals aren't paid under the OPPS, so the cut doesn't reach them.
Retail and contract pharmacy 340B prescriptions aren't part of this rule. It covers drugs that hospitals give in their outpatient departments, such as infusions and injections, and bill to Medicare Part B.
New modifiers on every drug line
From January 1, 2027, every separately payable drug on an OPPS claim needs one of three modifiers. CMS finalized ND as the permanent code for drugs not bought on 340B.
| Modifier | Meaning | Payment |
|---|---|---|
| JG | Bought on 340B, cut applies | ASP minus 28% |
| TB | Bought on 340B, hospital is exempt | Regular OPPS rate |
| ND | Not bought on 340B | Regular OPPS rate (generally ASP plus 6%) |
Can a hospital buy outside 340B for Medicare patients?
Yes, with care. In the final rule, CMS said: "If hospitals follow all required guidance and regulations, they may purchase outside of the 340B program as necessary." Hospitals can keep using 340B for other patients, such as those with commercial insurance.
CMS also reminded hospitals that dispensing or furnishing drugs solely to take advantage of payment differences, rather than based on the patient's medical needs, may raise concerns under federal fraud and abuse laws. Which account you buy from is a purchasing decision. Which drug a patient gets stays a clinical decision.
The drug-by-drug math
For each drug, compare two margins:
- On 340B: (ASP minus 28%) minus your 340B price
- Outside 340B: (ASP plus 6%) minus your non-340B price
Put simply, buying outside 340B pays more when your 340B discount, measured from your non-340B price, is smaller than about 34% of ASP.
| Example | ASP | Non-340B price | 340B price | Margin on 340B | Margin outside 340B | Better choice |
|---|---|---|---|---|---|---|
| Drug A (small 340B discount) | $1,000 | $1,050 | $770 | -$50 | +$10 | Outside 340B |
| Drug B (survey averages) | $1,000 | $1,027 | $666 | +$54 | +$33 | 340B |
| Drug C (deep 340B discount) | $1,000 | $1,050 | $300 | +$420 | +$10 | 340B |
These are made-up prices for illustration. Payment amounts include the patient's share and are before sequestration. In CMS's survey, hospitals' non-340B drug costs averaged 2.7% above ASP. At survey-average prices (Drug B), staying on 340B still pays a little more. Buying outside 340B wins mainly for drugs with small 340B discounts, so check each drug.
Watch the GPO ban
Under existing 340B law, not this rule, disproportionate share (DSH), children's and freestanding cancer hospitals can't buy covered outpatient drugs through a group purchasing organization (GPO). For a DSH hospital, a non-340B outpatient drug usually costs WAC, which shrinks the gain from buying outside 340B. Hospitals not under the GPO ban may come out ahead more often.
What to do before January 1
- List your top Medicare Part B drugs by spend.
- For each one, compare the two margins above using current ASP, 340B and non-340B prices.
- Set up split billing so the drugs you choose restock on the right account for Medicare patients.
- Make sure your billing system adds JG, TB or ND to every separately payable drug line.
- Put your decisions, and how often you'll review them, in your written 340B policies.
- Check payer contracts that pay a percentage of Medicare outpatient rates, including Medicare Advantage.
- Review prices each quarter, when ASPs update.
What could change
CMS said it expects to look at payment differences for 340B and non-340B drugs in future yearly rulemaking, so the rate and rules may change. We'll post updates in Recent Updates.
How Secure340B can help
- Drug-by-drug review: we compare 340B and non-340B margins for your Medicare Part B drugs using WAC, ASP and 340B ceiling prices, so you can decide with your own numbers.
- TrueView reporting: see how your 340B program performs today, including your Medicare Part B drugs. About TrueView
- Program management: split billing setup, policies and procedures, and quarterly reviews. About program management
Questions? Email Info@Secure340B.com or talk to our team.
Information current as of November 16, 2026. This is general information, not legal or billing advice. Confirm coding with CMS guidance and your compliance team. Sources: CMS CY 2027 OPPS final rule, Federal Register; Holland & Knight; Covington.
